Evusheld: A long-acting antibody combination for the prevention of COVID-19 in high-risk individuals
Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies, and materials for their technological significance that are available for sale or license. The R&D 100 Awards, celebrating the program's 60th Anniversary this year, has long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology. This 2022 R&D 100 winner is listed below, along with its respective category.
Category: Analytical/Test
Developers: Vanderbilt University
Co-Developers: Vanderbilt University Medical Center; AstraZeneca
United States
Product Description:The immune systems of the immunocompromised often fail to generate proper antibodies in response to a vaccination, leaving this large sub-population of people exposed to infection. Evusheld is an FDA EUA-approved antibody medicine for COVID-19 that is delivered via intramuscular injection and provides lifesaving protection to this highly vulnerable group.
Developers: Vanderbilt University
Co-Developers: Vanderbilt University Medical Center; AstraZeneca
United States
Product Description:The immune systems of the immunocompromised often fail to generate proper antibodies in response to a vaccination, leaving this large sub-population of people exposed to infection. Evusheld is an FDA EUA-approved antibody medicine for COVID-19 that is delivered via intramuscular injection and provides lifesaving protection to this highly vulnerable group.
Evusheld Photo